Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.
“CBSET has previously reported scientific data predicting lesion geometry following radiofrequency (RF) renal denervation treatment in preclinical models. Now, we encourage the industry to invest in further, mechanistic research to develop next-generation devices that more precisely and selectively deliver RF or other types of energy to the nerve-rich tissue compartments surrounding the renal artery wall.” Peter M. Markham, President and CEO, CBSET
LEXINGTON, Mass.–(BUSINESS WIRE)–March 26, 2014–
Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, are reminding thought leaders in renal denervation that there is a seminal experimental and computational template for the more rational, comprehensive preclinical evaluation and optimization of renal denervation devices that can be utilized during preclinical and clinical development.
CBSET will be exhibiting at 2014 annual scientific meeting of the
American College of Cardiology (ACC), March 29-31, Washington, DC, Booth #1561
“Now is not the time to panic on renal denervation; now is the time to expand our understanding of the mechanisms driving efficacy,” said Peter Markham, President, CEO and co-founder of CBSET. “Application of more advanced device designs, such as multi-electrode catheters, use of irrigation to protect the vascular intima, and different approaches such as ultrasound energy delivery or chemical denervation, will provide an exquisite opportunity to further elucidate these mechanisms in therapies including sympathetic denervation and other bioelectronic medicines. Therefore the door is still wide open to optimize therapies targeting the sympathetic nervous system, such as renal denervation.
“The disclosure of the Symplicity-3 data at ACC is a call to action for the scientific community to expand our knowledge base on critical issues surrounding renal denervation, including appropriate endpoints, clinical trial patient selection, and peri-operative biomarkers,” Markham said. “Studies like those recently disclosed by CBSET and those that will be reported by CBSET in the second quarter of this year formulate a template for a more rational and comprehensive preclinical evaluation and optimization of renal denervation devices.”
“CBSET has been able to provide a unique perspective on the determinants of efficacy in renal denervation devices and has, consequently, enabled the medical device industry to discriminate amongst different technologies and further refine treatment paradigms,” added Elazer Edelman, M.D., Ph.D., chairman and co-founder of CBSET. “Mechanistic research at institutions like CBSET will enhance the community’s ability to overcome early challenges in implementation of novel treatment protocols.”
The CBSET approach was first presented at “TCT 2013″ by Dr. Edelman* and combines quantitative histopathologic characterization of target microanatomy with computational modeling of energy distribution and ablation. The computational models developed by Dr. Rami Tzafriri, principal scientist at CBSET, help explain how to understand the impact of renal denervation and how to optimize this emerging technology. These studies in particular shed light on the importance of treatment parameters such as electrode power and duration, while also revealing the dependence of RF (radiofrequency) energy delivery on the structure of perivascular tissues that vary between individuals. Importantly, these data have broader impact beyond the treatment of drug-resistant hypertension. Additional data to be presented at “EuroPCR 2014″ in May will expand this understanding of how variable tissue anatomy and nerve distribution can lead to intra-patient variability, even with consistent energy application.
“The MedTech industry and scientific community need to expand our understanding of sympathetic denervation so we can begin to target other diseases in which the sympathetic nervous system plays a critical role, such as heart failure and obstructive sleep apnea,” said Dr. Erica Smith, Scientific Director of Business Development at CBSET. “The data presented at ACC will provide guidance on how to best approach drug-resistant hypertension as well as these other indications.”
About Renal Denervation and the New CBSET Paradigm for Preclinical Evaluation of RDN Devices
An increase in renal sympathetic nerve activity has been shown to be a significant contributing factor in developing chronic hypertension. Renal “denervation” seeks to interrupt the nerve signals between the kidneys and the brain that control the blood pressure response to certain stimuli. But, how best to “shut down” these nerve fibers located in the renal artery without surgery, and how can we know that the treatment is effective, safe and durable? Reduction of kidney norepinephrine (NEPI) is a critical biomarker for determining the efficacy of renal denervation; but, the analytical hurdles present in quantifying NEPI in the sub-endogenous range are daunting. Physiological levels of NEPI are miniscule – and NEPI is inherently unstable, subject to rapid metabolic and non-metabolic oxidative degradation. Nevertheless, accurate measurement of the reduction in NEPI perioperatively after neural ablation is essential to reliably compare novel technologies. Addressing complex analytical issues, CBSET has developed a novel HPLC-MS/MS assay that accurately quantifies NEPI concentrations in porcine kidney tissue. The innovative assay is specific, sensitive, stable, robust, and linear over three orders of magnitude; indeed, it has significantly upgraded assay performance and data reliability in the sub-endogenous range, allowing assessment of efficacy and aiding in the differentiation and selection of the best treatment for renal denervation.
For a copy of the CBSET data, visit CBSET’s booth exhibit #1561 during the ACC annual scientific meeting, or contact: Erica A. Smith, Ph.D., Scientific Director for Business Development, CBSET, +1-781-296-5319, firstname.lastname@example.org
CBSET – Concord Biomedical Sciences & Emerging Technologies – is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products.
* Electrode irrigation alters RF ablation treatment zone geometry and protects intimal and medial tissue while maintaining injury to renal nerves
John Keating1, Peter M. Markham1, James Stanley1, Rami Tzafriri1, Gee Wong1, Anna Spognardi1, Elazer R. Edelman2,3, et al.
1 CBSET Inc, 500 Shire Way, Lexington, MA
2 IMES, MIT, 77 Massachusetts Avenue, Cambridge, MA
3 Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
Our upcoming GrowthBeat event — August 5-6 in San Francisco — is exploring the data, apps, and science of successful marketing. Get the scoop here, and grab your tickets before they're gone!